1. Alkermes' major I-O hope sees progress in early cancer tests — Under pressure, Pfizer and others join Moderna in publishing COVID vaccine trial protocols — Survey finds nearly half of Americans would not get a COVID vaccine if it were available today — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Monday, After The Close.

Discussion in 'Amgen' started by Anonymous, Jan 21, 2011 at 3:19 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Here we are, almost Monday January 24, 2011. After the market close, 1PM, PT, the very important 4th quarter will be announced.

    This moment is very pivotal as it will reveal if the new Prolia/Xgeva is selling at significant figures.

    We really have nothing else to look at but, Amgen shows its worry by announcing new prices for our drugs. One analyst said it is being done to offset the lagging sales.

    They have tons of money but not a cent (dividend) for the shareholder. Shall we form a prayer circle? That might help.
     

  2. Anonymous

    Anonymous Guest


    If the earnings, and denosumab sales are not what the street hopes for, two things should happen, share price descends and overhead reduction announcements will be made. The sale of the Fremont facility is a start.
     
  3. Anonymous

    Anonymous Guest

    What's the consensus among the field force - are you sales of denosumab up, down, or flat?
     
  4. Anonymous

    Anonymous Guest

    Don't worry about the "field force", it's the analysts that set the pace along with the other money managers. The street consensus is $1.06 to $1.11 EPS.

    No one knows the deno sales figures. That will be announced this Monday.
     
  5. Anonymous

    Anonymous Guest

    The numbers will be awesome!!!
     
  6. Anonymous

    Anonymous Guest

    Fuckin r*****/dimwit

    J lenzo-ED of BHBU market access and right hand of HT is OUT now (replaced with SS-right hand of Rick R). Its a pretty clear sign for next days to come for Kirstin D and finally Helen T and over all dmab sales.

    Maybe new leadership will change the direction and morale somewhat!!!!!!!!!!!
     
  7. Anonymous

    Anonymous Guest

    Today (1-24-11) after the market close (1 PM PT), we get the whole picture where we are going, such as denosumab sales and the hoped for DIVIDEND.

    If we get positive comments on both, the shares will certainly rise.

    Also, look for comments about overhead adjustments.
     
  8. Anonymous

    Anonymous Guest

    SADLY, they are NOT awesome. (See today's 1-24-11... 1/4 and yearly numbers.)